Codexis, Inc.
200 Penobscot DrIve
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Since 2002, Codexis' works every day to unlock the power of proteins®!
Our vision for the future
We discover and develop more effective therapeutics, enable healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future. This unified vision is what drives Codexis to continually set high standards and raise expectations of what is possible and its impact on the world and communities around us.
Creating a sustainable world
Enabling sustainable processes and products is our priority towards reducing waste, pollution, and consumption. Enzymes, nature’s biocatalysts for millions of years, are significantly more safe for the environment than are chemicals. We engineer high-performance enzymes to enable industrial bioprocesses that address productivity needs without sacrificing the health of our planet.
Commitment to human health
We are committed to effective biological therapeutics and accurate health monitoring tools. Annually, Codexis participates in global Rare Disease Day and also hosts its own event, welcoming guests and patient support groups with onsite activities. Whether it is for novel pharmaceuticals, protein therapies, gene therapies, biosensors, or upstream research and development, our work – evolved enzymes – makes an impact on someone’s life daily. This is why we at Codexis continue to work harder and smarter; we believe every breath and every heartbeat matters.
Commitment to community
As a socially responsible company, Codexis strives to play a positive role by fostering a culture that promotes employee volunteering to support the communities where we operate. We participate in multiple initiatives throughout the year supporting local charitable organizations, Family Giving Tree, and Second Harvest Food Bank. To promote youth education, Codexis sponsors Future Protein Engineers, an online program encouraging innovation and creativity while having fun learning about science.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
44 articles with Codexis, Inc.
-
Codexis to Participate in Upcoming Healthcare Conferences - May 17, 2022
5/17/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in two upcoming investor conferences.
-
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
5/16/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its gene therapy programs are the subject of two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.
-
Codexis Reports First Quarter 2022 Financial Results
5/5/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
5/2/2022
Codexis, Inc. announced two poster presentations highlighting three of the Company’s gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.
-
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
4/21/2022
Codexis, Inc. and seqWell, Inc. announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions.
-
Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
4/12/2022
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA.
-
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
3/1/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42nd Annual Health Care Conference, being held virtually March 7-9, 2022.
-
Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2/24/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.
-
Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
2/10/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market.
-
Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
1/24/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CDX-6512 for the treatment of homocystinuria.
-
Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
12/15/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - Nov 19, 2021
11/19/2021
Codexis, inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming virtual investment conferences.
-
Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021
11/15/2021
Codexis, inc. announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments for homocystinuria and maple syrup urine disease at the 14th International Congress of Inborn Errors of Metabolism 2021, taking place from November 21 to November 24, 2021, in Sydney, Australia and virtually.
-
Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development
11/15/2021
Codexis, Inc. today announced the appointments of Karen Frechou-Armijo as Senior Vice President, Human Resources and Asli Aras, Ph.D., as Vice President, Corporate Development.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - Nov 09, 2021
11/9/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming virtual investment conferences.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
11/4/2021
Codexis, Inc. today announced a combined $10 million investment enabled by their SynBio Innovation Accelerator in the Series B funding round of Molecular Assemblies, Inc.
-
Codexis Reports Third Quarter 2021 Financial Results
11/4/2021
Codexis, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
11/3/2021
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of the first subject in a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108.
-
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
9/9/2021
Codexis, Inc. announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®.